Medicus Pharma (MDCX) CEO awarded 500,000 options at $0.36 exercise price

Rhea-AI Filing Summary

Medicus Pharma Ltd. reported that Chief Executive Officer Raza Bokhari received a grant of stock options covering 500,000 underlying common shares. The options have an exercise price of $0.36 per share and were granted as a compensation-related award, not an open-market purchase.

According to the disclosure, the options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year, providing staged earning of the award. Following this grant, Bokhari holds 500,000 stock options directly, which are scheduled to expire on June 3, 2031 if not exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bokhari Raza

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	500,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 500,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 500,000 options Exercise price: $0.36 per share Underlying common shares: 500,000 shares +4 more

7 metrics

Option grant size 500,000 options Stock Option (right to buy) granted to CEO Raza Bokhari

Exercise price $0.36 per share Conversion or exercise price of the stock options

Underlying common shares 500,000 shares Common Shares underlying the granted stock options

Post-grant option holdings 500,000 options Total derivative securities following the transaction

Grant date June 3, 2026 Date the stock option was granted

Expiration date June 3, 2031 Scheduled expiration of the stock options

Vesting schedule Quarterly over one year Four equal installments over one year from grant date

Key Terms

Stock Option (right to buy), exercise price, Common Shares, vest quarterly, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 0.3600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

vest quarterly financial

"The option is scheduled to vest quarterly in four equal installments"

expiration date financial

"expiration_date: 2031-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bokhari Raza

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.36	06/03/2026		A		500,000		(1)	06/03/2031	Common Shares	500,000	$0	500,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Medicus Pharma (MDCX) disclose for CEO Raza Bokhari?

The company disclosed that CEO Raza Bokhari received a grant of stock options for 500,000 underlying common shares. This award is a compensation-related acquisition, not an open-market share purchase or sale, and represents a new derivative position tied to Medicus Pharma’s common shares.

What is the exercise price of the new Medicus Pharma (MDCX) stock options granted to the CEO?

The granted stock options have an exercise price of $0.36 per common share. This means Bokhari can acquire up to 500,000 Medicus Pharma common shares at $0.36 each if he exercises the options before they expire, subject to the vesting schedule.

How and when do the Medicus Pharma (MDCX) CEO’s new stock options vest?

The options granted to CEO Raza Bokhari are scheduled to vest quarterly in four equal installments over one year. This quarterly vesting structure ties the full economic benefit of the 500,000-share option grant to continued service during that year.

When do the newly granted Medicus Pharma (MDCX) stock options to the CEO expire?

The granted stock options are scheduled to expire on June 3, 2031. If they are not exercised by that date, Bokhari’s right to buy up to 500,000 Medicus Pharma common shares at the $0.36 exercise price will lapse.

Did Medicus Pharma (MDCX) CEO buy or sell common shares in this Form 4 filing?

No common share purchases or sales were reported. The filing shows a grant of stock options, a derivative security, giving the CEO the right to buy 500,000 common shares at $0.36, subject to vesting, rather than an immediate stock trade.